EICHOR
● Enrolling By Invitation
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Condition: Heart Failure · Heart Failure NYHA Class II · Heart Failure NYHA Class III · Sponsor: CVRx, Inc.
About this study
The purpose of BENEFIT-HF is to demonstrate the safety and effectiveness of Baroreflex Activation Therapy (BAT) with the Barostim System in participants with heart failure, defined as NYHA Functional Class II or III, LVEF \< 50% and NT-proBNP \< 5,000 pg/mL despite being treated with Guideline-Directed Medical Therapies (medications and devices). It includes demonstration that treatment with the Barostim System, relative to usual care medical management, reduces the rate of all-cause mortality and Heart Failure Morbidity (Cardiac Transplant, Durable LVAD, or Worsening Heart Failure Events).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (7)
| Cardiology Associates of Mobile | Mobile, Alabama, United States | — |
| First Coast Cardiovascular Institute | Jacksonville, Florida, United States | — |
| Tallahassee Research Institute | Tallahassee, Florida, United States | — |
| BayCare Health Systems | Tampa, Florida, United States | — |
| North Central Heart | Sioux Falls, South Dakota, United States | — |
| Erlanger Health | Chattanooga, Tennessee, United States | — |
| CHRISTUS Trinity Mother Frances | Tyler, Texas, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07232030